Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Current Assets: 2020-2024

Historic Current Assets for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $1.0 billion.

  • Janux Therapeutics' Current Assets rose 49.79% to $998.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $998.1 million, marking a year-over-year increase of 49.79%. This contributed to the annual value of $1.0 billion for FY2024, which is 195.97% up from last year.
  • According to the latest figures from FY2024, Janux Therapeutics' Current Assets is $1.0 billion, which was up 195.97% from $349.2 million recorded in FY2023.
  • Janux Therapeutics' Current Assets' 5-year high stood at $1.0 billion during FY2024, with a 5-year trough of $16.1 million in FY2020.
  • Its 3-year average for Current Assets is $571.8 million, with a median of $349.2 million in 2023.
  • In the last 5 years, Janux Therapeutics' Current Assets soared by 2,247.27% in 2021 and then declined by 11.82% in 2022.
  • Janux Therapeutics' Current Assets (Yearly) stood at $16.1 million in 2020, then soared by 2,247.27% to $377.0 million in 2021, then dropped by 11.82% to $332.4 million in 2022, then rose by 5.05% to $349.2 million in 2023, then skyrocketed by 195.97% to $1.0 billion in 2024.